Guillain-Barré syndrome historical perspective: Difference between revisions
(Created page with "{{Guillain-Barré syndrome}} {{CMG}}; '''Associate Editors-In-Chief:''' Priyamvada Singh, MBBS [mailto:psingh@perfuse.org] ==Overview== '''Guillain-Barr...") |
|||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
'''Guillain-Barré syndrome''' ('''GBS''') is an acute, autoimmune, [[neuropathy|polyradiculoneuropathy]] affecting the [[peripheral nervous system]], usually triggered by an acute infectious process. It is included in the wider group of [[peripheral neuropathy|peripheral neuropathies]]. There are several types of GBS, but unless otherwise stated, GBS refers to the most common form, acute inflammatory demyelinating polyneuropathy (AIDP). It is frequently severe and usually exhibits as an ascending paralysis noted by weakness in the legs that spreads to the upper limbs and the face along with complete loss of deep tendon reflexes. With prompt treatment of [[plasmapheresis]] followed by [[immunoglobulins]] and supportive care, the majority of patients will regain full functional capacity. However, death may occur if severe pulmonary complications and [[dysautonomia]] are present. | '''Guillain-Barré syndrome''' ('''GBS''') is an acute, autoimmune, [[neuropathy|polyradiculoneuropathy]] affecting the [[peripheral nervous system]], usually triggered by an acute infectious process. It is included in the wider group of [[peripheral neuropathy|peripheral neuropathies]]. There are several types of GBS, but unless otherwise stated, GBS refers to the most common form, acute inflammatory demyelinating polyneuropathy (AIDP). It is frequently severe and usually exhibits as an ascending paralysis noted by weakness in the legs that spreads to the upper limbs and the face along with complete loss of deep tendon reflexes. With prompt treatment of [[plasmapheresis]] followed by [[immunoglobulins]] and supportive care, the majority of patients will regain full functional capacity. However, death may occur if severe pulmonary complications and [[dysautonomia]] are present. | ||
==Historical perspective== | |||
The disease was first described by the French physician Jean Landry in 1859. In 1916, Georges Guillain, Jean Alexandre Barré and Andre Strohl who diagnosed two soldiers with a discovered the key diagnostic abnormality of increased spinal fluid protein production, but normal cell count.<ref>{{WhoNamedIt2|synd|1766|Guillain-Barré-Strohl syndrome}} and {{WhoNamedIt|synd|1508|Miller Fisher's syndrome}}</ref> | |||
GBS is also known as ''acute inflammatory demyelinating polyneuropathy'', ''acute idiopathic polyradiculoneuritis'', ''acute idiopathic polyneuritis'', ''French Polio'' and ''Landry's ascending paralysis''. | |||
==References== | ==References== |
Revision as of 16:06, 15 February 2012
Guillain-Barré syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Guillain-Barré syndrome historical perspective On the Web |
American Roentgen Ray Society Images of Guillain-Barré syndrome historical perspective |
Risk calculators and risk factors for Guillain-Barré syndrome historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Priyamvada Singh, MBBS [2]
Overview
Guillain-Barré syndrome (GBS) is an acute, autoimmune, polyradiculoneuropathy affecting the peripheral nervous system, usually triggered by an acute infectious process. It is included in the wider group of peripheral neuropathies. There are several types of GBS, but unless otherwise stated, GBS refers to the most common form, acute inflammatory demyelinating polyneuropathy (AIDP). It is frequently severe and usually exhibits as an ascending paralysis noted by weakness in the legs that spreads to the upper limbs and the face along with complete loss of deep tendon reflexes. With prompt treatment of plasmapheresis followed by immunoglobulins and supportive care, the majority of patients will regain full functional capacity. However, death may occur if severe pulmonary complications and dysautonomia are present.
Historical perspective
The disease was first described by the French physician Jean Landry in 1859. In 1916, Georges Guillain, Jean Alexandre Barré and Andre Strohl who diagnosed two soldiers with a discovered the key diagnostic abnormality of increased spinal fluid protein production, but normal cell count.[1]
GBS is also known as acute inflammatory demyelinating polyneuropathy, acute idiopathic polyradiculoneuritis, acute idiopathic polyneuritis, French Polio and Landry's ascending paralysis.